Medical treatment of cervical intraepithelial neoplasia II, III: An update review

International Journal of Clinical Oncology

Volumn 14, Issue 1, 2009, Pages 37-42

  Kietpeerakool, Chumnan ^a   Srisomboon, Jatupol ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Cervical dysplasia; Cervical intraepithelial neoplasia; Conservative treatment; Medical treatment

Indexed keywords

3 INDOLEMETHANOL; ALITRETINOIN; BETA CAROTENE; CANCER VACCINE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; FENRETINIDE; FOLIC ACID; HEAT SHOCK PROTEIN; HYBRID PROTEIN; MVA E2 RECOMBINANT VACCINE; PLACEBO; PLASMID DNA; PROTEIN E7; RETINOIC ACID; RETINOID; ROFECOXIB; UNCLASSIFIED DRUG; ZYC 101A; ZYC101A;

ABSENCE OF SIDE EFFECTS; ADENOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RESEARCH; CANCER STAGING; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIARRHEA; DIET THERAPY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; HUMAN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; INJECTION SITE SWELLING; NAUSEA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA IN SITU; VAGINA IRRITATION;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GENE THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASM STAGING; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 60649093969     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0795-x     Document Type: Review

References (61)

1. J.M. Walboomers M.V. Jacobs M.M. Manos 1999 Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J Pathol 189 12 19
2. N. Munoz F.X. Bosch S. de Sanjose 2003 Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 518 527
3. A.G. Ostor 1993 Natural history of cervical intraepithelial neoplasia: a critical review Int J Gynecol Pathol 12 186 192
4. M.F. Mitchell W.N. Hittelman W.K. Hong 1994 The natural history of cervical intraepithelial neoplasia: an argument for intermediate endpoint biomarkers Cancer Epidemiol Biomarkers Prev 3 619 626
5. T.C. Wright Jr. L.S. Massad C.J. Dunton 2007 2006 Consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ Am J Obstet Gynecol 197 340 345
6. A.B. Moscicki M. Schiffman S. Kjaer 2006 Chapter 5: updating the natural history of HPV and anogenital cancer Vaccine 24 Suppl3 S42 S51
7. C. Kietpeerakool J. Srisomboon P. Suprasert 2007 Routine prophylactic application of Monsel's solution after loop electrosurgical excision procedure of the cervix: is it necessary? J Obstet Gynaecol Res 33 299 304
8. P.A. Hillard F.M. Biro L. Wildey 1991 Complications of cervical cryotherapy in adolescents J Reprod Med 36 711 716
9. M. Jakobsson M. Gissler S. Sainio 2007 Preterm delivery after surgical treatment for cervical intraepithelial neoplasia Obstet Gynecol 109 309 313
10. M.C. Bell P. Crowley-Nowick H.L. Bradlow 2000 Placebo-controlled trial of indole-3-carbinol in the treatment of CIN Gynecol Oncol 78 123 129
11. Y. Dai X. Zhang Y. Peng 2005 The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma Gynecol Oncol 97 96 103
12. P. Dursun K. Yuce A. Usubutun 2007 Cyclooxygenase-2 expression in cervical intraepithelial neoplasia III and squamous cell cervical carcinoma, and its correlation with clinicopathologic variables Int J Gynecol Cancer 17 164 173
13. J.S. Lee Y.D. Choi J.H. Lee 2004 Expression of cyclooxygenase-2 in adenocarcinomas of the uterine cervix and its relation to angiogenesis and tumor growth Gynecol Oncol 95 523 529
14. B.S. Reddy Y. Hirose R. Lubet 2000 Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis Cancer Res 60 293 297
15. E. Hawk R. Lubet P. Limburg 1999 Chemoprevention in hereditary colorectal cancer syndromes Cancer 86 2551 2563
16. J.H. Farley V. Truong E. Goo 2006 A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor celecoxib in the treatment of cervical dysplasia Gynecol Oncol 103 425 430
17. L.A. Hefler C. Grimm P. Speiser 2006 The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III A phase II trial Eur J Obstet Gynecol Reprod Biol 125 251 254
18. S.D. Solomon J.J. McMurray M.A. Pfeffer 2005 Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 352 1071 1080
19. R.S. Bresalier R.S. Sandler H. Quan 2005 Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 1092 1102
20. I.V. Boiko M.F. Mitchell W. Hu 1998 Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial Clin Cancer Res 4 1383 1391
21. E.W. Gerner F.L. Meyskens Jr 2004 Polyamines and cancer: old molecules, new understanding Nat Rev Cancer 4 781 792
22. N. Seiler F. Raul 2005 Polyamines and apoptosis J Cell Mol Med 9 623 642
23. M.F. Mitchell G. Tortolero-Luna J.J. Lee 1998 Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia Clin Cancer Res 4 303 310
24. A.T. Vlastos L.A. West E.N. Atkinson 2005 Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3 Clin Cancer Res 11 390 396
25. F.L. Meyskens Jr E. Gilmartin D.S. Alberts 1982 Activity of isotretinoin against squamous cell cancers and preneoplastic lesions Cancer Treat Rep 66 1315 1319
26. F.L. Meyskens Jr V. Graham M. Chvapil 1983 A phase I trial of beta-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia J Natl Cancer Inst 71 921 925
27. E.A. Surwit V. Graham W. Droegemueller 1982 Evaluation of topically applied trans-retinoic acid in the treatment of cervical intraepithelial lesions Am J Obstet Gynecol 143 821 823
28. S.A. Weiner E.A. Surwit V.E. Graham 1986 A phase I trial of topically applied trans-retinoic acid in cervical dysplasia - clinical efficacy Invest New Drugs 4 241 244
29. F.L. Meyskens Jr E. Surwit T.E. Moon 1994 Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial J Natl Cancer Inst 86 539 543
30. M. Follen E.N. Atkinson D. Schottenfeld 2001 A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix Clin Cancer Res 7 3356 3365
31. R.D. Alvarez M.G. Conner H. Weiss 2003 The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial Cancer Epidemiol Biomarkers Prev 12 114 119
32. M.T. Ruffin J.M. Bailey D.P. Normolle 2004 Low-dose topical delivery of all-trans retinoic acid for cervical intraepithelial neoplasia II and III Cancer Epidemiol Biomarkers Prev 13 2148 2152
33. Helm CW, Lorenz DJ, Meyer NJ, et al. (2007) Retinoids for preventing the progression of cervical intra-epithelial neoplasia. Cochrane Database Syst Rev 4:CD003296
34. A. Kwasniewska A. Tukendorf M. Semczuk 2997 Folate deficiency and cervical intraepithelial neoplasia Eur J Gynaecol Oncol 18 526 530
35. C.J. Piyathilake O.L. Henao M. Macaluso 2004 Folate is associated with the natural history of high-risk human papillomaviruses Cancer Res 64 8788 8793
36. R.L. Sedjo P. Inserra M. Abrahamsen 2002 Human papillomavirus persistence and nutrients involved in the methylation pathway among a cohort of young women Cancer Epidemiol Biomarkers Prev 11 353 359
37. C.J. Piyathilake M. Macaluso I. Brill 2007 Lower red blood cell folate enhances the HPV-16-associated risk of cervical intraepithelial neoplasia Nutrition 23 203 210
38. C.E. Butterworth Jr K.D. Hatch S.J. Soong 1992 Oral folic acid supplementation for cervical dysplasia: a clinical intervention trial Am J Obstet Gynecol 166 803 809
39. J.M. Childers J. Chu L.F. Voigt 1995 Chemoprevention of cervical cancer with folic acid: a phase III Southwest Oncology Group Intergroup study Cancer Epidemiol Biomarkers Prev 4 155 159
40. P.R. Palan M.S. Mikhail J. Basu 1992 Beta-carotene levels in exfoliated cervicovaginal epithelial cells in cervical intraepithelial neoplasia and cervical cancer Am J Obstet Gynecol 167 1899 1903
41. A. Manetta T. Schubbert J. Chapman 1996 Beta-carotene treatment of cervical intraepithelial neoplasia: a phase II study Cancer Epidemiol Biomarkers Prev 5 929 932
42. S.L. Romney G.Y. Ho P.R. Palan 1997 Effects of betacarotene and other factors on outcome of cervical dysplasia and human papillomavirus infection Gynecol Oncol 65 483 492
43. K.A. Keefe M.J. Schell C. Brewer 2001 A randomized, double blind, phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia Cancer Epidemiol Biomarkers Prev 10 1029 1035
44. H.L. Bradlow J. Michnovicz N.T. Telang 1991 Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice Carcinogenesis 12 1571 1574
45. G. van Poppel D.T. Verhoeven H. Verhagen 1999 Brassica vegetables and cancer prevention. Epidemiology and mechanisms Adv Exp Med Biol 472 159 168
46. V.P. Garikapaty B.T. Ashok Y.G. Chen 2005 Anticarcinogenic and anti-metastatic properties of indole-3-carbinol in prostate cancer Oncol Rep 13 89 93
47. V.P. Garikapaty B.T. Ashok K. Tadi 2006 3,3?-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer Biochem Biophys Res Commun 340 718 725
48. M. Qi A.E. Anderson D.Z. Chen 2005 Indole-3-carbinol prevents PTEN loss in cervical cancer in vivo Mol Med 11 59 63
49. K.J. Auborn S. Fan E.M. Rosen 2003 Indole-3-carbinol is a negative regulator of estrogen J Nutr 133 2470S 2475S
50. B. Klencke M. Matijevic R.G. Urban 2002 Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101 Clin Cancer Res 8 1028 1037
51. E.E. Sheets R.G. Urban C.P. Crum 2003 Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA Am J Obstet Gynecol 188 916 926
52. F. Garcia K.U. Petry L. Muderspach 2004 ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial Obstet Gynecol 103 317 326
53. C. Rosales V.V. Graham G.A. Rosas 2000 A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity Cancer Immunol Immunother 49 347 360
54. C.M. Corona Gutierrez A. Tinoco M. Lopez Contreras 2002 Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus Hum Gene Ther 13 1127 1140
55. C.M. Corona Gutierrez A. Tinoco T. Navarro 2004 Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus Hum Gene Ther 15 421 431
56. E. Garcia-Hernandez J.L. Gonzalez-Sanchez A. Andrade-Manzano 2006 Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine Cancer Gene Ther 13 592 597
57. U. Zugel S.H. Kaufmann 1999 Immune response against heat shock proteins in infectious diseases Immunobiology 201 22 35
58. S.E. Goldstone J.M. Palefsky M.T. Winnett 2002 Activity of HspE7, a novel immunotherapy, in patients with anogenital warts Dis Colon Rectum 45 502 507
59. C.S. Derkay R.J. Smith J. McClay 2005 HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial Ann Otol Rhinol Laryngol 114 730 737
60. M.H. Einstein A.S. Kadish R.D. Burk 2007 Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III Gynecol Oncol 106 453 460
61. L.D. Roman S. Wilczynski L.I. Muderspach 2007 A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia Gynecol Oncol 106 558 566